Neximmune Inc (NEXI)

NASDAQ
10.67
-1.31(-10.93%)
  • Volume:
    30,805
  • Bid/Ask:
    8.07/12.29
  • Day's Range:
    10.53 - 12.51

NEXI Overview

Prev. Close
11.98
Day's Range
10.53-12.51
Revenue
-
Open
12
52 wk Range
10.53-28
EPS
-
Volume
30,805
Market Cap
240.92M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
22,579,219
Next Earnings Date
Dec 01, 2021
What is your sentiment on Neximmune Inc?
or
Market is currently closed. Voting is open during market hours.

Neximmune Inc News

  • Neximmune EPS beats by $0.10
    • BySeeking Alpha-

    Neximmune (NEXI): Q1 GAAP EPS of -$0.71 beats by $0.10.Cash and cash equivalents of $118.1MPress Release

  • Neximmune reports FY results
    • BySeeking Alpha-

    Neximmune (NEXI): FY GAAP EPS of -$26.42.Cash and cash equivalents of $5MPress Release

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellBuy
SummaryStrong SellStrong SellStrong SellStrong SellNeutral

Neximmune Inc Company Profile

Neximmune Inc Company Profile

Sector
Services
Employees
44

NexImmune, Inc is a clinical-stage biotechnology company. The Company is engaged in developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. The Company provides Artificial Immune Modulation (AIM) which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. Its T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. The Company’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation and multiple myeloma refractory to lines of therapy, respectively.

Read More
  • Lets see where this goes in a few years
    0
    • With emerging A.I. and nanoparticle technology merging in the next few months and years, especially with their mission to use targeted treatments for cancer, this should do very well
      0
    • Ryan Flanaganleta bope thats the case they are a new kid on the ipo block so . Only time will tell
      0
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.